IQVIA Reports Third-Quarter 2026 Results
Business Wire•27/10/2026•07:00 ET
0
Key Highlights
- ➤Revenue $4,428 million, up 8.0% year-over-year
- ➤Adjusted diluted EPS $3.34, up 11.3% year-over-year
- ➤R&D Solutions net new bookings $3.2 billion, up 15% year-over-year
- ➤FY2026 guidance raised: revenue $17,350-$17,500 million; adjusted EPS $12.90-$13.00
- ➤Free cash flow $667 million, representing 120% of Adjusted Net Income
Expert Statements
Ari Bousbib, Chairman and CEO of IQVIA
“IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations. Multiple demand indicators continue to validate the strengthening market environment. EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends, and pipeline growth across clinical and commercial are all favorable. At the same time, the team's ongoing excellent execution delivered margin expansion, strong free cash flow, higher win rates that resulted in our strongest clinical quarterly bookings since 2022, increased penetration of AI-powered solutions with over 400 AI agents deployed to date, and organic growth acceleration year-over-year to double the rate for commercial and nearly triple the rate for clinical.”
Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency
* GAAP Net Income $350 million, Adjusted EBITDA $1,032 million, up 8.7% year-over-year
Get started
Create a free account to read the full story.